Praxis Precision Medicines (PRAX) Enterprise Value (2019 - 2026)

Praxis Precision Medicines' Enterprise Value history runs 8 years deep, the most recent figure standing at -$786.9 million for Q1 2026.

• In Q1 2026, Enterprise Value fell 139.9% year-over-year to -$786.9 million; the TTM figure through Mar 2026 stood at -$786.9 million (down 139.9% YoY), while the FY2025 annual figure was -$599.3 million, down 52.67% from the prior year.
• Enterprise Value for Q1 2026 stood at -$786.9 million, down from -$599.3 million in the prior quarter.
• The five-year high for Enterprise Value was -$56.0 million in Q2 2022, with the low at -$786.9 million in Q1 2026.
• The 5-year median for Enterprise Value is -$207.4 million (2024), against an average of -$249.2 million.
• The sharpest annual moves came in 2022 and 2024: Enterprise Value soared 68.14% in 2022, then tumbled 382.86% in 2024.
• Praxis Precision Medicines' Enterprise Value stood at -$61.6 million in 2022, then slumped by 31.95% to -$81.3 million in 2023, then sank by 382.86% to -$392.6 million in 2024, then sank by 52.67% to -$599.3 million in 2025, then plunged by 31.29% to -$786.9 million in 2026.
• Business Quant data shows PRAX's Enterprise Value at -$786.9 million in Q1 2026, -$599.3 million in Q4 2025, and -$267.2 million in Q3 2025.